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Platelet activating factor receptor blockade ameliorates murine
systemic lupus erythematosus
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with the technical assistance of EDITH HANZMANN
Departments of Medicine, Physiology and Biophysics, and Pathology, Case Western Reserve University, Cleveland, Ohio, USA
Platelet activating factor receptor blockade ameliorates murine sys-
temic lupus erythematosus. Untreated 16-week-old MRL/MpJ-lpr/lpr
(lpr) mice, when compared to congenic MRL/MpJ-+/+ (+1+) mice, are
characterized by a systemic lupus erythematosus syndrome, including
severe glomerulonephntis, proteinuria and reduction of renal function.
We hypothesized that platelet activating factor (PAF), a potent chemo-
tactic and proinfiammatory phospholipid mediator synthesized and
released by circulating cells, glomerular mesangial and renal medullary
interstitial cells, may play a role in the development of renal injury in
lupus mice. We assessed renal PAF synthesis in lpr as well as +1+ mice
and the effect of treatment with a PAF receptor blocking agent.
Treatment with the PAF receptor antagonist L659,989 for four weeks,
starting at 12 weeks of age, significantly reduced acute glomerular
infiltration and proliferation, and prevented chronic glomerular histo-
logical changes; proteinuria and serum creatinine levels were also
significantly reduced in treated mice. Renal PAF production was
increased in lpr when compared to +1+ mice, and treatment with
L659,989 restored renal PAF synthesis to the control levels. Our results
support the hypothesis that PAF can be one of the mediators of
glomerular injury characteristic of murine lupus nephritis, and indicate
the possible therapeutic utility of PAF receptor antagonists in immu-
nologic renal diseases.
Mice of the MRL/MpJ-lpr/lpr (lpr) strain spontaneously de-
velop a lymphoproliferative syndrome associated with systemic
autoimmune disease, including skin, heart and joint lesions, and
a chronic, progressive renal injury, remarkably similar to the
glomerulonephritis characteristic of systemic lupus erythema-
tosus (SLE) [I]. Consequently, lpr mice are considered a good
experimental model of lupus, potentially useful in assessing the
effectiveness of therapeutic approaches to lupus nephritis.
The phospholipid platelet activating factor (PAF), identified
as 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphocholine, is a potent
mediator of inflammation, released by cells present in inflam-
matory exudates [21. PAF causes aggregation and degranulation
of platelets, neutrophils and basophils, thus contributing to the
amplification of the inflammatory process [2]. A potent renal
vasoconstrictor, PAF decreases renal blood flow and glomeru-
lar filtration rate [3, 4]. Because PAF provokes mesangial
contraction [5], it likely decreases the ultrafiltration coefficient
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and further contributes to the reduction of glomerular filtration
rate. Moreover, PAF synthesis is increased in cultured glomer-
ular mesangial cells in response to different stimuli [6—9], and
hence PAF may modulate cell function in an autocrine fashion.
Increased synthesis of PAF in various experimental models
of glomerular immune injury has already been demonstrated
[10—13]. Also, the beneficial effects of a treatment with a PAF
receptor antagonist in the treatment of immune complex and
nephrotoxic serum nephritis have been documented [10, 13].
We designed a protocol to study the effects of a new PAF
receptor antagonist, L659,989, on the development of glomer-
ulonephritis in lpr mice at 12 to 16 weeks of age. L659,989 is a
potent, third generation PAF receptor antagonist, active orally
(ED50 0.2 mg/kg), and characterized by a long duration of action
of 12 to 16 hours [14, 15]. To assess the possible therapeutic
efficacy, we performed morphological and biochemical studies,
including measurements of renal PAF, POE2 and TxA2 synthe-
sis.
We report that renal PAF synthesis is increased in MRL/
MpJ-lpr/lpr mice when compared to age-matched congenic
MRL/MpJ-+/+. Also, our data indicate that treatment with
L659,989 decreases the severity and incidence of proteinuria,
reduces glomerular proliferation and infiltration, and decreases
renal PAF synthesis.
Methods
Chemicals
L659,989 was synthesized and provided by Merck Research
Laboratories (Rahway, New Jersey, USA). [3H]-acetate was
purchased from ICN (Costa Mesa, California, USA), and
arachidonic acid from Cayman Chemical (Ann Arbor, Michi-
gan, USA). All other reagents were from Sigma Chemical Co.
(St. Louis, Missouri, USA).
Mice
Female MRL/MpJ-lpr/lpr (lpr) and congenic female MRL/
MpJ-+/+ (+1+) mice were purchased from Jackson Laboratory
(Bar Harbor, Maine, USA). They were kept under standard
laboratory conditions in the Animal Resource Center until 12
weeks old. At 11 and 12 weeks of age, 20-hour urine specimens
were collected from each animal, and proteinuria and hematuria
were evaluated. Animals with proteinuria greater than 0.7
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mg/24 hours at 12 weeks of age were not included in the
protocol.
Experimental design
Four groups of mice were studied: group 1, 22 lpr mice
received the drug-vehicle (0.5% methylcellulose) for four
weeks; group 2, 22 lpr mice received two oral doses per day of
L659,989 (5 mg/kg/day); group 3, 20 +1+ mice received the
drug-vehicle; and group 4, 20 +1+ mice received two oral doses
of L659,989 (5 mg/kg/day). All animals were treated for four
weeks and sacrificed at 16 weeks of age. The drug was admin-
istered directly into the stomach through an oral feeding can-
nula. Additional age-matched mice of each strain (lpr and +1+)
were sacrificed at 12 weeks of age, when drug or vehicle
administration was begun.
We assessed the adequacy of PAF receptor blockade in
control female mice by preventing the effect of an intravenous
lethal dose of PAF (25 Lg/kg) [16] three hours after a single oral
administration of 5 mg/kg of L659,989.
Twenty-hour urine specimens were collected weekly from lpr
animals; urines from +1+ mice were collected before and at the
end of the treatment. Urines were collected under mineral oil by
placing individual mice in metabolic cages. All mice were
weighed weekly.
At the end of the treatment period, mice were anesthetized
with ether, the abdomen opened and blood drawn by cardiac
puncture. The animals were then perfused via the aorta with
0.9% NaC1 (40 ml or until the kidneys became white). Kidneys
were removed, and specimens collected for light microscopy,
electron microscopy, immunofluorescence and microsome
preparation.
Urinary protein and creatinine evaluation
Urine specimens were tested with Chemstrip (Boehnnger
Mannheim, Indianapolis, Indiana, USA) for determination of
hematuria and presence of leukocytes, centrifuged at 2000 X g
for 20 minutes and the supernate aliquoted and stored at —40°C
until assayed. Urinary protein concentrations were determined
by turbidimetry in 3% sulfosalycylic acid. The protein concen-
tration in each specimen was multiplied by the urine volume,
and by a factor of 1.2, to express the 24 hour excretion based on
a 20 hour collection. Serum creatinine concentrations were
measured by a routine method using an autoanalyzer (Chem 1,
Technicon Corp, Tarrytown, New York, USA).
Renal morphology and morphometry
Part of the renal tissue was fixed in 10% buffered formalin for
light microscopic histopathological evaluation using coded
slides. Sections of paraffin-embedded tissue were stained with
periodic acid-Schiff. Alterations were scored according to Pass-
well et al [171 and the acuity and chronicity indices based on
human SLE by Austin et al [18]. Using the classification of
Passwell et al [17], histological changes were evaluated for: a)
acute glomerulonephritis (GN), b) glomerulosclerosis (GS) and
c) interstitial inflammation (IN). Scores were given from 0 to 4
for each category, based on the severity of the changes.
Glomerular and tubular infiltration of monocytes, lympho-
cytes, platelets and neutrophils were assessed by cellular and
nuclear morphology in histochemical preparations of paraffin
tissue by light microscopy. Each cell type was separately
counted in each of nine glomeruli from each sample.
Small pieces of kidney cortex were fixed in Karnovsky's
solution for electron microscopy evaluation.
Immunofluorescence
Part of the upper pole of one kidney from each mouse was
quickly frozen in cold 2-methylbutane immersed in liquid
nitrogen, and stored at —70°C. Immunofluorescent staining was
done as previously reported [191, using fluorescein-conjugated
IgG fractions of goat antisera specific for mouse IgG or mouse
complement C3, all diluted at 1:20 (U.S. Biochemicals, Cleve-
land, Ohio, USA). Coded sections were examined in a epifluo-
rescence microscope (E. Leitz, Wetzlar, FRG). Based on
immunofluorescent intensity of C3 and IgG staining observed in
+1+ mice, the lpr mice were scored as negative or positive for
C3, and 2 and >2 for IgG immunodeposition.
Preparation of microsomal fractions
Kidneys were weighed, minced with scissors and homoge-
nized in 10 volumes of 0.1 MTris-HCI, pH 7, containing 0.3 M
sucrose, using a Polytron homogenizer (The Virtis Company,
Gardiner, New York, USA). The homogenate was centrifuged
at 12,500 x g for 20 minutes at 4°C and the resultant supernate
centrifuged at 100,000 x g for 60 minutes at 4°C. The pellets
were resuspended with a glass-teflon homogenizer in 0.1 M
Tris-HCI (pH 7), 7 mti CaCI2, 5 mr,i dithiothreitol, 0.5 mM
EGTA for determination of PAF acetyltransferase activity and
in 0.1 M Tns-HCI (pH 8), 1 mM EDTA, 3 mri reduced
glutathione for determination of prostaglandin biosynthesis.
Aliquots of microsomal fractions were frozen in liquid nitrogen,
kept at —80°C, and assayed within three to four days after
preparation. Protein concentration was determined by the
Coomassie Blue method (BIO-RAD protein assay reagent,
BlO-RAD Lab., Richmond, California, USA), using bovine
serum albumin as standard.
Assay ofLyso-PAF: Acetyl CoA : PAF acetyliransferase
activity
We assessed renal PAF synthesis by measuring [3H]-acetate
incorporation into PAF by kidney microsomes [20]. The
method used to determine the activity of acetyltransferase was
similar to that described by Wykle, Malone and Snyder [21].
The incubation medium (final volume 800 l) contained (final
concentrations): 0.1 M Tris-HC1 (pH 7), 7 mrs CaCl2, 5 mM
dithiothreitol, 0.5 mri EGTA, 30 pM lyso-PAF and 0.45 Ci
[H]-acetate (specific activity: 0.5 Cilmmol). Preliminary exper-
iments with kidney microsomes showed maximal incorporation
of [3H]-acetate into PAF at 10 minutes incubation (data not
shown); the enzyme activity was linear with protein concentra-
tion up to 200 pg (data not shown). The reaction was started by
adding microsomes (100 g protein), and the mixture incubated
in a shaking water bath at 37°C for 10 minutes. All the
measurements were performed in duplicate and repeated in
duplicate. The reaction was stopped by adding 3 ml of acidified
chloroform:methanol (1:2, vol/vol, pH 3). Lipids were ex-
tracted according to Bligh and Dyer [22]. Briefly, 1 ml of
chloroform and 1 ml of water were added, and the samples
centrifuged to effect a phase separation. The clear, lower
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chloroform phase was removed, washed once with 3.2 ml of
methanol: water (10:9, vol/vol), dried under a stream of nitro-
gen and resuspended in chloroform: methanol (9: 1, vol/vol).
The samples were applied to heat-activated TLC plates (Silica
gel 60, Merck, Darmstadt, FRG) and developed in
chloroform: methanol: water (65:35:6 vollvollvol). The labeled
phospholipid products were identified by co-chromatography
with known standards. The Rf value for PAF was 0.2. The lipid
fractions were visualized by 2-p-toluidinyl naphthylene 6-sul-
fonate (TNS) exposure and areas corresponding to PAF were
carefully scraped and the radioactivity counted by liquid scin-
tillation. In order to evaluate whether L659,989 directly affected
microsomal acetyltransferase activity, in four experiments mi-
crosome preparations were preincubated for five minutes at
37°C with increasing concentrations (0.1 to 100 /LM) of the
compound, and the experiments performed as described above.
Jdentjfication of (3H]-PAF-like material as authentic PAF
We tested PAF-like material, isolated as described above, for
its ability to aggregate washed rabbit platelets. For PAF bioas-
say, 5 x i0 platelets were gently stirred at 37°C in Tris-buffered
Tyrode's solution supplemented with 0.25% gelatin, in the
presence of 10 M indomethacin, and 31 pg/ml creatine phos-
phate [8]. The amount of PAF-like material present in the
samples was calculated with a calibration curve of authentic
PAF for which the minimum effective aggregating concentra-
tion was 10 M and the EC50 was 2 flM. In some experiments,
aliquots of the samples were pretreated with 30 m sodium
hydroxide in methanol at 22°C for five minutes to inactivate
PAF by deacylation. Also, the ability of L659,989 (10 sM) to
block platelet aggregation induced by the sample was tested.
Assay of prostaglandin biosynthesis
TxA2 (measured as its stable metabolite TxB2) and PGE2
formation in kidney microsomes was measured according to
Yoshimoto, Ito and Tomita [23], with minor modifications.
Briefly, 100 p1 of microsomes were incubated at 37°C in a
shaker water bath with 100 p1 buffer containing (final concen-
trations): 0.1 M Tris-HCI pH 8, 50 LM arachidonic acid, 300 nM
hemoglobin, 0,5 mrt EDTA and 1.5 m reduced glutathione.
Arachidonic acid was previously diluted to 15 m concentra-
tion with 0.6% NaHCO3. The reaction was stopped with 300 p1
of chloroform: methanol (1: 1, vol/vol), and the mixture evapo-
rated in a speed vacuum evaporator (Savant Instruments Inc.,
Farmingdale, New York, USA). The dry samples were recon-
stituted in the assay buffer, sonicated for 15 seconds, centri-
fuged to remove protein particles, and assayed by RIA for both
TxB2 and PGE2 as previously reported [24]. In preliminary
experiments, microsome prostaglandin biosynthesis was maxi-
mal after 15 minutes incubation and was linear up to 300 g
protein (data not shown). Accordingly, assays were performed
incubating 100 sg of microsomal protein at 37°C for 20 minutes.
Statistical analysis
Quantitative results are expressed as means SEM and
analyzed by one-way analysis of variance and Student's 1-test
for paired and unpaired data. Categorical classification data on
the renal pathology, expressed as median half range, were
analyzed by chi squared analysis.
Table 1. Characteristics of MRL lpr/lpr and MRL MPJ-+/+ mice at
the end of the treatment period
Body wt
g
Kidney wt
mg
MRL MPJ-+/+ 39.3 3.9 211.3 5.6
drug-vehicle
(20)
MRL MPJ-+/+ 39.1 0.7 193.4 3,9a
L659,989 (20)
MRL lpr/lpr 39.6 0.8 234.1 10.8
drug-vehicle
(22)
MRL lpr/lpr 37.9 1.1 197.7 48b
L659,989 (22)
Numbers in parentheses are the number of animals.
a p < 0.05 vs. vehicle-treated +1+
b P < 0.005 vs. vehicle-treated lpr
Results
Characteristics and mortality rate of MRL/MpJ-lpr/lpr and
MRL/MpJ-+I+ mice
Body weight and kidney weight of the four groups of mice are
reported in Table 1. There were no differences among the
animals in body weight, whereas average kidney weight was
significantly higher in drug-vehicle treated when compared to
L659,989-treated mice. One lpr animal in the vehicle treated
group died before the end of the treatment, at 15 weeks of age.
No deaths were observed in the L659,989-treated group.
Urinary protein levels and plasma creatinine activity
Average urinary protein levels in treated and untreated +1+
mice at 12 and 16 weeks of age are reported in Figure I.
Drug-vehicle treated mice showed only a slight increase of
urinary protein levels when compared to the basal values at 12
weeks of age. None of these mice had detectable urinary blood
or leukocytes.
Mean urinary protein levels before and during the treatment
period in lpr mice treated with L659,989 or the drug vehicle are
also shown in Figure 1. At the end of the treatment period, 73%
of drug-vehicle treated animals had urinary protein levels
greater than 0.5 mg124 hr, compared to 32% of L659,989 treated
animals ( = 7.38, P < 0.01). Moreover, the average urinary
protein level in drug-vehicle treated mice at 16 weeks of age,
was significantly greater than the basal level (4.44 1.5 mg124
hr, vs. 0.39 0.03, P < 0.05), but unchanged (0.87 0.27 mg/24
hr, vs. 0.36 0.03, P = NS) in treated mice (Fig. 1). Interest-
ingly, in the drug-vehicle treated animals, proteinuria started to
develop earlier, at 13 to 14 weeks of age (Fig. 1). Therefore, the
treatment with L659,989 for four weeks both reduced and
delayed the development of proteinuria in lpr mice. Further-
more, at the end of the treatment period, 50% of the drug-
vehicle treated lpr mice had high amounts of hemoglobin (50 to
250 erythrocytes/pi) and leukocytes (2+) in the urine, whereas
only 27% of the L659,989 treated animals had detectable
amounts of hemoglobin (10 erythrocytes/p1) or leukocytes
(trace to 2+; data not shown).
Average serum creatinine levels in the four groups of mice at
the end of treatment are shown in Figure 2. As expected, lpr
mice had significantly greater serum creatinine levels when
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Fig. 1. Urinary protein levels in the 4 groups of mice. Vehicle-treated
lpr mice had significantly greater urinary protein excretion at the
second, third and fourth week of treatment when compared to basal
levels (*P < 0.05). Values greater than 0.5 mg124 hours (dashed
horizontal line, corresponding to the mean 2 SD levels found in +1+
mice) were considered pathological. The number of mice in each group
is indicated in parentheses.
compared to the congenic +1+ mice. PAF receptor blockade
prevented much of the increase of serum creatinine concentra-
tion (P < 0.05 vs. untreated lpr mice), although the mean
creatinine level in treated lpr mice was still significantly greater
than that of control animals.
Histopathological features
By light microscopy, +1+ mice did not show any evidence of
renal morphological abnormalities at 12, 14 and 16 weeks of age
(Fig. 3A). In these animals, treatment with L659,989 did not
modify renal histological appearance. Twelve-week-old lpr
mice showed diffuse, mild to moderate, mesangial proliferative
glomerulonephritis, with rare focal segmental endocapillary
extension. No signs of chronic changes were present at this age
(Fig. 3B). At 16 weeks of age, lpr mice given vehicle alone
showed moderate to severe, diffuse mesangial matrix expansion
and hypercellularity, with or without additional segmental
occlusion of capillary lumens and thickening of glomerular
capillary walls, in association with occasional crescents, syn-
echiae, tuft necrosis and more prominent, less localized inter-
stitial infiltrates (Fig. 3, C and D). Few mice had extensive
crescent formation, focal signs of necrosis, or hyalinosis and
focal global sclerosis. Frequencies of low and high scores for
H
+1+ +1+ lpr lpr
vehicle L659,989 vehicle 1659,989
(20) (20) (22) (21)
Fig. 2. Mean serum creatinine levels in the 4 groups of mice at the end
of the treatment period. Lpr mice had significantly greater serum
creatinine levels (*P < 0.001) when compared to +1+ mice. L659,989-
treated lpr mice had significantly lower serum creatinine values when
compared to vehicle-treated lpr mice (AP < 0.05). The number of mice
in each group is indicated in parentheses.
the different classifications in vehicle- and L659,989-treated lpr
mice are reported in Table 2. Treatment with L659,989 signifi-
cantly reduced the frequency and the grade of acute and chronic
glomerular changes and interstitial fibrosis (Table 2). In partic-
ular, none of the drug-treated mice had crescents, synechiae,
tuft necrosis or glomerulosclerosis (Fig. 3, E and F); no signs of
chronic changes were observed. In addition, mesangial prolif-
eration was milder and only a few mice in this group had
segmental endocapillary proliferation and capillary wall thick-
ening. Among these, some had more widespread interstitial
infiltrates (Fig. 3F).
Platelets and neutrophils were not seen in interstitial infil-
trates, which were mainly lymphocytes and, in part, monocytes
and macrophages. Glomerular infiltrates by platelets, mono-
cytes, and neutrophils were not significantly different between
treated and untreated lpr mice (data not shown), although there
was a tendency for less severe neutrophil infiltrates in treated
animals (0.79 0.10 neutrophils/glomerulus in untreated and
0.54 0.10 in treated mice, P = 0.09).
No immunofluorescent staining was observed for C3 in +1+
mice; however, all mice had positive immunofluorescent stain-
ing for IgG, which was not affected by PAF receptor blockade
(data not shown). Moderate or intense IgG and C3 staining was
seen in lpr mice given the vehicle or L659,989 (data not shown).
There were no differences in the intensity or frequency of
staining for IgG or C3 between the two lpr groups, although all
the lpr mice had significantly greater frequencies and mean
scores for both IgG and C3 deposition when compared to +1+
mice (data not shown).
By electron microscopy, no electron dense deposits were
found in +1+ mice at any age, whereas virtually all lpr mice
studied, regardless of the treatment, had mesangial and irregu-
larly distributed, variably sized, subendothelial electron dense
deposits (Fig. 4, A through D). In many fields the subendo-
thelial deposits were very large (1000 nm) and occasionally
there were areas of lucency or resorption around the deposits.
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Fig. 3. Renal histology in +1+ and lpr mice. Glomeruli in +1+ mice at 16 weeks of age showed uniform equivocal mesangial expansion (A); at
12 weeks of age, lpr mice revealed focal-segmental mesangial proliferative glomerulonephritis (B). By 16 weeks of age, all vehicle-treated lpr mice
had diffuse moderate to severe mesangial proliferative glomerulonephritis and one-half showed focal-segmental endocapillary lesions within
markedly swollen glomeruli (C). In addition, one-third of the vehicle-treated lpr mice manifested focal glomerular sclerosis and/or crescents (0).
In contrast, one third of L659,989-treated 16 week old lpr mice each showed equivocal (not shown, similar to A), mild (E) or moderate (F) diffuse
mesangial proliferative glomerulonephritis. Interstitial infiltrates (seen in F) were present focally in both untreated and L659,989-treated lpr mice
at 16 weeks of age. All PAS-stained sections, final magnification 306x.
7.,.. 2'# M_ _'-f.L .S . Ss • •
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Table 2. Frequency of chronicity and acuity, and ON, GS and IN scores in yehide- and L659,989-treated MRL Ipr/lpr mice
Acuitya Chronicitya GNb GSb INb
4 >4 0 >0 <1 >1 0 >0 0 >0
MRL lpr/lpr
vehicle
MRL lpr/lpr
L659,989
0
9
22
12C
17
21
5
QC
0
7
22
14d
14
20
8
1"
I
4
21
17
Abbreviations are: ON, glomerulonephritis; GS, glomerulosclerosis; EN, interstitial nephritis.
Significance versus vehicle:
a
according to Austin et al (18]b
according to Passwell et al (17]
P < 0.001d P < 0.01
Fig. 4. Electron microscopic appearance in lpr mice. Numerous subepithelial and subendothelial deposits are evident in a representative
16-week-old untreated lpr mouse (x 12750) (A); numerous subepithelial deposits of uniform size and a few subendothelial deposits show some
resorptive change in another 16-week-old untreated lpr mouse (x 19125) (B); numerous large subendothelial deposits and numerous small
subepithelial deposits similar to those in (A) and (B) are also seen in a 16-week-old treated lpr mouse (x 12750) (C); partially resolved
subendothelial and subepithelial deposits are also present in a different 16-week-old treated lpr mouse (x 19125) (D). The size, density, number
and distribution of deposits in treated lpr mice (C and D) were not different from those in the untreated lpr mice (A and B).
In 75% of the L659,989-treated and in 84% of the untreated
animals there were irregular subepithelial deposits. There were
no differences in the frequency, size or distribution of electron
dense deposits between treated and untreated lpr mice.
The light microscopic observation of mesangial and endocap-
illary proliferation, and leukocytic infiltration were confirmed
by electron microscopy.
PAF biosynthesis in kidney microsomes
PAF synthesis by kidney microsomes in the four groups of
mice is summarized in Figure 5. The most striking finding was
the increase of renal PAF synthesis in lpr mice when compared
to age matched +1+ mice (565.8 77.6 cprriIg protein vs.
281.2 42.8 cpm/g protein, P < 0.05). Increased renal PAF
synthesis was also found in 14-week-old lpr mice (data not
shown). Interestingly, treatment of lpr mice with the PAF
receptor antagonist completely eliminated the increased renal
PAF synthesis in the lpr mice (Fig. 5). In order to rule out a
direct effect of L659,989 we evaluated a five minute preincuba-
tion of kidney microsomes with increasing concentrations (0.1
to 100 LM) of L659,989; no inhibition of acetyltransferase
activity was seen (data not shown).
Neither glomerular infiltrates of platelets, monocytes, and
neutrophils, nor tubulo-interstitial infiltrates of lymphocytes,
monocytes and macrophages correlated with PAF acetyltrans
ferase activity in kidney microsomes. However, there was a
trend to significant correlation between PAF synthesis and
interstitial neutrophil infiltration (r = 0.42, P = 0.06). [3H]-
material co-migrating with authentic PAF isolated from kidney
microsomes was able to induce aggregation of rabbit platelets
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+1+
vehicle
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L659,989
lpr
vehicle
lpr
L659,989
(15) (15) (15) (15)
Fig. 5. Average PAF synthesis by kidney microsomes in the 4 groups
of mice. Vehicle-treated Ipr mice showed significantly greater PAF
synthesis when compared to untreated or treated +1+ mice (* < 0.0l),
or to L659,989-treated mice (&P < 0.05). The number of mice for each
group is indicated in parentheses.
which was completely inhibited by L659,989 or by alkaline
methanolic hydrolysis of the sample (data not shown). We
estimated that 100 p.g kidney microsomal preparation produced
approximately 15 pmoles bioactive PAF.
Prostaglandin biosynthesis in kidney microsomes
TxA2 and PGE2 synthesis in kidney microsomal preparations
was significantly higher in vehicle-treated lpr when compared to
age matched +1+ mice (Fig. 6). There was no correlation
between renal cycloxygenase activity and glomerular infiltrates
of platelets, monocytes and neutrophils, or tubulo-interstitial
infiltrates of lymphocytes, monocytes and macrophages. Treat-
ment with L659,989 did not significantly affect microsomal
eicosanoid synthesis.
Discussion
The present results show that four weeks of treatment with
the PAF receptor antagonist L659,989 ameliorates the renal
pathology and functional derangements associated with sys-
temic lupus erythematosus (SLE) in MRL/MpJ-lpr/lpr mice.
We also found increased renal PAF synthesis in lpr mice when
compared to age-matched congenic control animals, which was
reduced by L659,989. Our findings are consistent with a medi-
ator role for PAF in the renal disease which develops in lpr
mice.
We evaluated the effect of four weeks of treatment with
L659,989 on several renal parameters: urinary protein excre-
tion, serum creatinine levels and renal morphologic changes.
The compound L659,989 is a potent third generation PAF
receptor antagonist with inhibition constants for PAF binding in
the flM range [14, 15]. L659,989 is active orally in female rats
and is characterized by a long duration of action of 12 to 16
hours [14]. We found that PAF receptor blockade with
Fig. 6. Renal microsoma! TxA2 (measured as its stable metabolite
TxB2) and PGE2 synthesis in the 4 groups of mice. Synthesis of both
compounds was significantly increased in vehicle-treated lpr mice when
compared to control +1+ mice (* < 0,001). L659,989-treated lpr mice
manifested renal eicosanoid synthesis at intermediate levels that did not
differ statistically from untreated lpr mice. The number of mice for each
group is indicated in parentheses.
of proteinuria.
Serum creatinine levels, although still elevated when com-
pared to control animals, were significantly decreased in the
L659,989-treated animals. This finding also indicates less severe
glomerular injury in L659,989-treated animals. Renal morpho-
logical studies verified less severe acute and chronic glomerular
damage in drug-treated animals. In particular, no signs of
chronic changes and no glomerular crescents were found in
treated mice. Interestingly, renal histological appearance of
L659,989-treated lpr mice at 16 weeks of age resembled that
found in the same mice at 12 weeks of age, indicating that PAF
receptor blockade protected these animals from the progressive
renal damage which develops with aging in the untreated mice.
No differences were observed in density, size or distribution
of electron dense deposits between treated and untreated lpr
mice. Moreover, electron dense deposits of similar size and
density were also present in lpr mice at the beginning of the
treatment. This finding indicates that PAF receptor blockade
may likely interfere with the processes that follow the deposi-
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L659,989 significantly reduced the degree and the frequency of
proteinuria, leukocyturia and hematuria. Moreover, the time
course of urinary protein excretion in the individual animals
revealed a different pattern in the development of proteinuria in
the PAF blocked animals, indicating that the treatment with the
PAF receptor antagonist delayed the onset of proteinuria.
Camussi et al [25] have shown that acute PAF infusion in
rabbits induces transient proteinuria due to release of cationic
proteins derived from PAF-stimulated platelets and neutrophils
and consequent loss of glomerular anionic charges. The treat-
ment with a PAF receptor antagonist may interfere with this
process, inhibiting PAF-induced activation of inflammatory
leukocytes within the glomerulus, thus reducing development
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tion of immune complexes in the glomeruli, rather than with
formation and deposition itself.
As already mentioned, renal PAF synthesis was increased in
16-week-old lpr mice when compared to age-matched controls.
We have also proven that PAF receptor blockade restored renal
PAF synthesis to the control levels. In the kidney, PAF can be
synthesized by infiltrating inflammatory cells [2, 26] as well as
by mesangial [6—9], tubular and medullary cells [27]. In partic-
ular, the Fe fragment of immunoglobulin can stimulate PAF
synthesis in cultured mesangial cells [9]. This mechanism could
be activated in vivo in lpr mice following deposition of immune
complexes, thus partially explaining the increased renal acetyl-
transferase activity observed in these mice. Moreover, the
increase of glomerular parenchymal cells as well as infiltrating
cells observed in lpr mice may also account for the greater
acetyltransferase activity found in these mice when compared
to +1+. In particular, there was a tendency to correlation
between glomerular neutrophil infiltration and acetyltransferase
activity in the kidney, indicating that this cell type may be
partly responsible for increased enzyme activity. Similarly,
Lianos and Zanglis [28] reported in a recent paper that in-
creased renal PAF levels observed in heterologous phase
nephrotoxic serum nephritis was due both to increased renal
parenchymal cells and infiltrating cells, particularly platelets.
To our knowledge there are no reports describing the mitogenic
effects of PAF on renal parenchymal cells; however, PAF has
been shown to increase thymidine incorporation in cultured
vascular smooth muscle cells [29], suggesting a possible mito-
genic effect of PAF. Moreover, PAF may stimulate synthesis
and release of other mitogens from both infiltrating and paren-
chymal cells, as has been demonstrated for interleukin-l [30,
31]. Increased gene expression for interleukin-l in kidneys of
MRL/MpJ-lpr/lpr mice has been recently reported [32]; this
increase appears to be correlated with the degree of proteinuria
and seems to be generated, at least in part, by cells infiltrating
the glomeruli [32]. Furthermore, the presence of positive stain-
ing for platelet-derived growth factor in the kidneys of patients
with lupus nephritis suggests a role for this platelet-derived
mitogen [33]. These findings suggest an involvement of factors
released by activated, infiltrating, inflammatory cells and
mesangial cells in the development of lupus nephritis. PAF
receptor blockade may inhibit PAF-stimulated release of mito-
genie substances, thus explaining the decreased proliferation
found in L659,989-treated mice. Lesser hypercellularity may
also explain the reduced microsomal PAF synthesis observed in
treated mice. Alternatively or in addition, the decreased renal
PAF synthesis after PAF receptor blockade could be explained
by an inhibition by L659,989 of autostimulated PAF synthesis
within the glomeruli, as PAF itself can be a stimulus for PAF
production, at least in neutrophils [34]. Moreover, although in
vitro addition of L659,989 to renal microsomal preparations did
not affect acetyltransferase activity, a direct in vivo effect of
L659,989 on the enzyme activity cannot be excluded.
Increased TxA2, but not PGE2, production in both kidney
cortex and medulla of lpr mice has been documented by Kelley,
Sulve and Musinky [35]. This increase has been partly ex-
plained by the increased renal inflammatory infiltrate charac-
teristic of lupus [35]. In our study, using whole kidney microso-
mal preparations, we found increased synthesis of both TxA2
(as indicated by the amount of its stable metabolite TxB2) and
PGE2 in lpr mice at 16 weeks of age. Unlike PAF synthesis,
L659,989-treated mice showed intermediate levels of renal
cyclooxygenase activity, that were not significantly different
from either untreated lpr or control mice.
In conclusion, we have shown an increased microsomal
acetyltransferase and cyclooxygenase activity in the kidneys of
MRL/MpJ-lpr/lpr mice; furthermore, the oral administration of
a PAF receptor antagonist for four weeks significantly de-
creased glomerular synthesis of PAF in parallel with attenuated
glomerular damage and improved renal function in treated
mice. These data suggest a role for PAF in the pathogenesis of
renal injury associated with murine SLE, and indicate the
possible therapeutic use of PAF receptor antagonists in the
treatment of lupus nephritis.
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